EchoPulse receives CE mark approval


Theraclion has received the CE mark approval for EchoPulse, a non-invasive treatment of breast fibroadenomas, a first in this indication.

Echotherapy is a non-invasive therapeutic approach with ultrasound-guided focused ultrasound, in which high-intensity focused ultrasounds (10,000 times higher than normal ones) are used for a specifically localised ablation with no skin damage. The ultrasounds are focused on a small area where the temperature rise leads to tissue necrosis. This treatment precision avoids harming healthy tissues around the lesion. The echotherapy is a technique that enables practitioners to simultaneously visualise and treat a tumour such as fibroadenoma with no incision or scar.

This article is tagged to:
Sector: Medical Devices
Geography: Europe, France